What information should I provide to adult or adolescent (≥16 years) patients with narcolepsy type 1 who request Orzeyful (orexin‑2‑receptor agonist) regarding its indication, dosing, contraindications, side effects, and follow‑up?

What to Tell Patients Asking for Orzeyful

Orzeyful is NOT indicated for narcolepsy type 1 and should not be prescribed for this condition. According to FDA labeling, Orzeyful is indicated only for "temporary relief of weak memory and concentration, anxiousness, or indigestion due to sensitivity to phenolic compounds found in foods or other products" 1. This is a completely different indication than narcolepsy treatment.

The Confusion: Orexin Agonists vs. Orzeyful

Your patient may be confusing Orzeyful with oveporexton (TAK-861), which is an orexin receptor 2-selective agonist that has shown remarkable efficacy for narcolepsy type 1 in recent Phase 3 trials 2. These are entirely different medications:

Oveporexton (the actual narcolepsy medication):

• Mechanism: Oral orexin-2 receptor agonist that directly addresses the underlying orexin deficiency in narcolepsy type 1
• Efficacy data: In two Phase 3 trials, oveporexton improved mean sleep latency on the Maintenance of Wakefulness Test by 14.3-19.8 minutes versus -0.4 to -0.8 minutes with placebo (P<0.001) 2
• Cataplexy reduction: 79.0-88.8% reduction in weekly cataplexy rate versus 27.7-39.1% with placebo (P<0.001) 2
• Common side effects: Increased urinary frequency and transient insomnia (occurred in majority of participants, but insomnia typically resolved within 1 week) 3

Orzeyful (what the patient is asking about):

• A homeopathic or alternative medicine product for phenolic compound sensitivity
• No evidence for narcolepsy treatment
• Dosing: 10 drops under tongue up to 3 times daily 1

What to Recommend Instead

For adult patients with narcolepsy type 1, the American Academy of Sleep Medicine (2021) provides STRONG recommendations for four first-line agents 4:

1. Modafinil (STRONG recommendation)

   • Most robust evidence: 9 RCTs and 4 observational studies
   • Improves excessive daytime sleepiness, disease severity, and quality of life
   • Schedule IV controlled substance
   • Common adverse events: insomnia, nausea, diarrhea, headache, dry mouth
   • Reduces oral contraceptive effectiveness 4

2. Pitolisant (STRONG recommendation)

   • Improves excessive daytime sleepiness, cataplexy, and disease severity
   • Available only through specialty pharmacies
   • Common adverse events: headache, insomnia, weight gain, nausea
   • Reduces oral contraceptive effectiveness 4

3. Sodium oxybate (STRONG recommendation)

   • Schedule III controlled substance with black box warning for CNS depression and respiratory depression
   • Available only through REMS program with certified pharmacies
   • Addresses both sleepiness and cataplexy 4

4. Solriamfetol (STRONG recommendation)

   • Schedule IV controlled substance
   • High-quality evidence for improving excessive daytime sleepiness and disease severity
   • Common adverse events: headache, decreased appetite, insomnia, nausea, chest discomfort (mostly mild-moderate) 4

Conditional recommendations (second-line):

• Armodafinil, dextroamphetamine, methylphenidate 4

Clinical Approach

Start with one of the four STRONG recommendation medications based on:

• Cataplexy present: Consider sodium oxybate or pitolisant (both address cataplexy directly)
• Cataplexy absent or mild: Consider modafinil or solriamfetol first
• Pregnancy potential: All agents have insufficient human data; modafinil/armodafinil registry shows higher congenital anomaly rates 4
• Substance abuse concerns: Avoid Schedule II agents (dextroamphetamine, methylphenidate); prefer modafinil, pitolisant, or solriamfetol
• Insurance/cost considerations: Modafinil typically most accessible; pitolisant requires specialty pharmacy 4

Key Counseling Points

Tell the patient directly:

• Orzeyful has no role in narcolepsy treatment and is not FDA-approved for this indication
• If they read about "orexin agonists," they likely mean oveporexton, which is a prescription medication currently in clinical trials (not yet widely available)
• Evidence-based treatments with STRONG recommendations exist now and should be initiated
• All current narcolepsy medications provide symptomatic relief; oveporexton represents a future disease-modifying approach but is not yet standard of care 5, 6

Common Pitfall

Patients may encounter online information about breakthrough orexin agonist therapies and confuse product names. Always clarify what specific medication they're asking about and redirect to guideline-concordant therapy while acknowledging the exciting future of orexin-targeted treatments.